JP2017528464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528464A5 JP2017528464A5 JP2017513207A JP2017513207A JP2017528464A5 JP 2017528464 A5 JP2017528464 A5 JP 2017528464A5 JP 2017513207 A JP2017513207 A JP 2017513207A JP 2017513207 A JP2017513207 A JP 2017513207A JP 2017528464 A5 JP2017528464 A5 JP 2017528464A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- cell
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CN1C2CC(*)CC1CCC2 Chemical compound CN1C2CC(*)CC1CCC2 0.000 description 2
- FPVBKYJZDGHIIV-LJSVPSOQSA-N C[C@H](C1)C23C1N(C)C2CC3 Chemical compound C[C@H](C1)C23C1N(C)C2CC3 FPVBKYJZDGHIIV-LJSVPSOQSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048771P | 2014-09-10 | 2014-09-10 | |
| US62/048,771 | 2014-09-10 | ||
| US201462078845P | 2014-11-12 | 2014-11-12 | |
| US62/078,845 | 2014-11-12 | ||
| US201562146790P | 2015-04-13 | 2015-04-13 | |
| US62/146,790 | 2015-04-13 | ||
| PCT/US2015/049235 WO2016040515A1 (en) | 2014-09-10 | 2015-09-09 | Substituted piperidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528464A JP2017528464A (ja) | 2017-09-28 |
| JP2017528464A5 true JP2017528464A5 (enExample) | 2018-10-18 |
Family
ID=55459535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513207A Pending JP2017528464A (ja) | 2014-09-10 | 2015-09-09 | 置換ピペリジン化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10577363B2 (enExample) |
| EP (1) | EP3193605A4 (enExample) |
| JP (1) | JP2017528464A (enExample) |
| KR (1) | KR20170047397A (enExample) |
| CN (1) | CN107072207A (enExample) |
| AU (1) | AU2015315182A1 (enExample) |
| BR (1) | BR112017004589A2 (enExample) |
| CA (1) | CA2960280A1 (enExample) |
| EA (1) | EA201790327A1 (enExample) |
| IL (1) | IL250888A0 (enExample) |
| MX (1) | MX2017002986A (enExample) |
| SG (2) | SG10201901189SA (enExample) |
| WO (1) | WO2016040515A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015315180A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Isoxazole carboxamides as irreversible SMYD inhibitors |
| BR112017004612A2 (pt) | 2014-09-10 | 2018-01-30 | Epizyme, Inc. | compostos, composição farmacêutica, usos de um composto, e kit |
| JP2017526706A (ja) | 2014-09-10 | 2017-09-14 | エピザイム，インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| US10106510B2 (en) | 2014-09-10 | 2018-10-23 | Epizyme, Inc. | Substituted isoxazoles for treating cancer |
| JP6610905B2 (ja) * | 2015-02-27 | 2019-11-27 | オーピーバイオファクトリー株式会社 | カケロマイシンおよびその誘導体の製造方法 |
| MA45782B1 (fr) * | 2016-07-28 | 2021-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| WO2019145460A1 (en) * | 2018-01-26 | 2019-08-01 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| US12213970B2 (en) | 2018-10-29 | 2025-02-04 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| KR102812426B1 (ko) | 2018-10-29 | 2025-05-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도 |
| EP4039331A4 (en) | 2019-09-30 | 2024-01-17 | Nippon Chemiphar Co., Ltd. | Azepan derivative |
| CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| CN117800895A (zh) * | 2022-09-30 | 2024-04-02 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
| WO2025133989A1 (en) * | 2023-12-20 | 2025-06-26 | Alt-Bio Pte. Ltd. | Smyd modulators and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228288B (it) * | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SE0403106D0 (sv) | 2004-12-20 | 2004-12-20 | Astrazeneca Ab | Chemical compounds |
| WO2008137834A2 (en) * | 2007-05-04 | 2008-11-13 | Osi Pharmaceuticals, Inc. | Crystal structure of smyd3 protein |
| AR069526A1 (es) * | 2007-12-03 | 2010-01-27 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| ES2617339T3 (es) * | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| WO2016040508A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| BR112017004612A2 (pt) | 2014-09-10 | 2018-01-30 | Epizyme, Inc. | compostos, composição farmacêutica, usos de um composto, e kit |
| AU2015315180A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Isoxazole carboxamides as irreversible SMYD inhibitors |
| US20170253601A1 (en) | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
| US10106510B2 (en) | 2014-09-10 | 2018-10-23 | Epizyme, Inc. | Substituted isoxazoles for treating cancer |
| JP2017526706A (ja) * | 2014-09-10 | 2017-09-14 | エピザイム，インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
-
2015
- 2015-09-09 CA CA2960280A patent/CA2960280A1/en not_active Abandoned
- 2015-09-09 CN CN201580060918.8A patent/CN107072207A/zh active Pending
- 2015-09-09 EA EA201790327A patent/EA201790327A1/ru unknown
- 2015-09-09 EP EP15840497.0A patent/EP3193605A4/en not_active Withdrawn
- 2015-09-09 MX MX2017002986A patent/MX2017002986A/es unknown
- 2015-09-09 US US15/510,588 patent/US10577363B2/en active Active
- 2015-09-09 JP JP2017513207A patent/JP2017528464A/ja active Pending
- 2015-09-09 BR BR112017004589A patent/BR112017004589A2/pt not_active Application Discontinuation
- 2015-09-09 SG SG10201901189SA patent/SG10201901189SA/en unknown
- 2015-09-09 WO PCT/US2015/049235 patent/WO2016040515A1/en not_active Ceased
- 2015-09-09 AU AU2015315182A patent/AU2015315182A1/en not_active Abandoned
- 2015-09-09 KR KR1020177009316A patent/KR20170047397A/ko not_active Withdrawn
- 2015-09-09 SG SG11201701597RA patent/SG11201701597RA/en unknown
-
2017
- 2017-03-02 IL IL250888A patent/IL250888A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528464A5 (enExample) | ||
| JP2017527577A5 (enExample) | ||
| JP2017538659A5 (enExample) | ||
| CN115485277B (zh) | 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶 | |
| JP6884102B2 (ja) | がんの治療のための化合物 | |
| JP2024138293A (ja) | バイオマーカー型治療用組成物 | |
| CA2807620C (en) | Pharmaceutically active compounds as axl inhibitors | |
| JP2016514695A5 (enExample) | ||
| Chen et al. | Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC | |
| JP2023512174A (ja) | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン | |
| JP2022551668A5 (enExample) | ||
| JP5323289B1 (ja) | 新規ピペリジン化合物又はその塩 | |
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| JP2019514950A5 (enExample) | ||
| MA40581A (fr) | Dérivés pyridone utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) | |
| JP2011515397A5 (enExample) | ||
| JP2016525509A5 (enExample) | ||
| EA201691939A1 (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона | |
| JP2022541633A (ja) | がんの治療のためのｅｚｈ２阻害併用療法 | |
| CA3094449A1 (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| ES2980476T3 (es) | Derivados de tienopiridina y composición farmacéutica que los contiene | |
| JP2015518894A5 (enExample) | ||
| JP2015518899A5 (enExample) | ||
| JP2017527577A (ja) | 置換ピロリジン化合物 | |
| SI2054418T1 (sl) | Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji |